Instead of managing symptoms, newer treatments aim to correct underlying metabolic dysfunction
Peptides in the 4,000-6,000 dalton range can be delivered nasally with enhancement, as demonstrated by insulin research
Photos represent real patients from physician-supervised GoalBMI Wellness programs shared with patient consent
A post hoc analysis of the phase IIb trial showed that tirzepatide was associated with a reduction in the level of high-sensitivity ICAM-1, CRP, and YKL-40 after 26 weeks of treatment in a dose-dependent manner [83, 103]
4CD), indicating protection against mitochondrial dysfunction
Predictors of De Novo Nonalcoholic Fatty Liver Disease After Liver Transplantation and Associated Fibrosis